{Reference Type}: Journal Article
{Title}: Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer.
{Author}: Su X;Sun X;Wang Y;Kang Y;Dai Y;Su X;Sun X;Wang Y;Kang Y;Dai Y;
{Journal}: Pak J Med Sci
{Volume}: 38
{Issue}: 6
{Year}: Jul-Aug 2022
{Factor}: 2.34
{DOI}: 10.12669/pjms.38.6.5287
{Abstract}: <B>UNASSIGNED: </B>To investigate the clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on the levels of antigen cluster protein 133 (CD133) and human epididymal secretory protein 4 (HE4) in patients with advanced epithelial ovarian cancer (EOC).<BR><B>UNASSIGNED: </B>A total of 104 patients with advanced EOC hospitalized in Affiliated Hospital of Hebei Engineering University from April 2015 to December 2018 were assigned to two groups using a random number table. A control group (n =52) treated by the conventional postoperative TP regimen and an observation group (n =52) receiving HIPEC in addition to the conventional postoperative TP regimen. CD133 and HE4 expression in serum, overall response rate (ORR), long-term efficacy, and incidence of drug toxicity were measured for comparative analysis.<BR><B>UNASSIGNED: </B>The serum levels of CD133 and HE4 expression in the observation group were lower than in the control group (P < 0.005, respectively); the observation group surpassed the control group in ORR, 2-year survival, and progression-free survival (PFS) (P < 0.005, respectively); however, the two groups had no statistically significant difference in the incidence of drug toxicity (P > 0.05).<BR><B>UNASSIGNED: </B>TP-based HIPEC can effectively inhibit CD133 and HE4 expression in advanced EOC, which thereby improves the clinical efficacy and encourages longer survival.